Emisphere to Present at Rodman and Renshaw 17th Annual Global Investment Conference
GlobeNewswire - Wed Sep 02, 3:15PM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that President and Chief Executive Officer, Alan L. Rubino, will present at the Rodman and Renshaw 17 Annual Global Investment Conference at 9:35 AM ET on Wednesday, September 9, 2015. The Rodman and Renshaw conference is being held at The St. Regis Hotel in New York City.
Novo Nordisk to Start PIONEER Program on Semaglutide
Zacks Equity Research - Zacks Investment Research - Thu Aug 27, 2:30PM CDT
Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.
NVO: 54.61 (-0.12), MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Emisphere Reports Second Quarter 2015 Financial Results
GlobeNewswire - Wed Aug 12, 7:01AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the quarter ended June 30, 2015, and provided a corporate update.
Emisphere Announces Second Quarter 2015 Financial Results Conference Call
GlobeNewswire - Thu Aug 06, 3:30PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that Management will host a conference call on Wednesday, August 12, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the second quarter ended June 30, 2015.
Emisphere's Undervalued Diabetes Pill Partnership Is An Oversized Opportunity
PLM Investments - at Seeking Alpha - Fri Jun 26, 7:33AM CDT
NVO: 54.61 (-0.12)
Expect Novo Nordisk To Commit To Their Late-Stage Diabetes Pill Development Soon
PLM Investments - at Seeking Alpha - Thu Jun 18, 6:32AM CDT
NVO: 54.61 (-0.12)
Emisphere Technologies' (EMIS) CEO Alan Rubino on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri May 15, 1:10PM CDT
Emisphere Reports First Quarter 2015 Financial Results
GlobeNewswire - Fri May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the first quarter ended March 31, 2015, and provided an overview of corporate accomplishments and plans.
Emisphere Announces First Quarter 2015 Financial Results Conference Call
GlobeNewswire - Mon May 11, 3:15PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Friday, May 15, 2015, at 8:30 AM EDT to discuss the Company's financial and operational results for the quarter ended March 31, 2015.
Emisphere Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 6:50AM CDT
Recent Launch of Eligen B12(TM) Marks Company's Expansion into Commercializing Practical Innovation
Emisphere Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
GlobeNewswire - Wed Mar 25, 3:20PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Tuesday, March 31, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the quarter and twelve months that ended December 31, 2014.
Key Aspects Of A Potential Novo Nordisk Oral GLP-1 Phase 3 Trial
PLM Investments - at Seeking Alpha - Fri Mar 20, 10:52AM CDT
NVO: 54.61 (-0.12)
Penny Stocks Alerts for Sabine Oil & Gas, HDS International, Integral Technologies, Quicksilver Resources, FLEXPOWER, and Emisphere
PR Newswire - Thu Mar 19, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Sabine Oil & Gas (OTCMKTS:SOGC), HDS International (OTCMKTS:HDSI), Integral Technologies (OTCMKTS:ITKG), Quicksilver Resources (OTCMKTS:KWKA), FLEXPOWER (OTCMKTS:FLXP), and Emisphere Technologies (OTCMKTS:EMIS).
Emisphere Launches Eligen B12(TM), the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection
PR Newswire - Thu Mar 19, 7:15AM CDT
Emisphere Technologies, Inc. (OTCBB: EMIS) today announced the U.S. commercial availability of Eligen B12(TM), the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the need for an injection. Eligen B12 is indicated for the dietary management of patients who have a medically-diagnosed vitamin B12 deficiency, associated with a disease or condition that cannot be managed by a modification of the normal diet alone.
Novo Nordisk Is In The NASH Space, Too
PLM Investments - at Seeking Alpha - Wed Mar 18, 6:52PM CDT
NVO: 54.61 (-0.12), GILD: 100.65 (-0.16), ICPT: 181.90 (-8.81)
Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
PLM Investments - at Seeking Alpha - Thu Feb 19, 10:25AM CST
NVO: 54.61 (-0.12)
Emis Group's (EMIS) CEO Alan Rubino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:25PM CST
Emisphere Tech Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:13AM CST
Emisphere Technologies EPS of -$0.24
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:36AM CST